Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a focus on marine economy and health products as key growth drivers [2] Financial Performance - The company achieved operating revenue of 417 million yuan, a year-on-year increase of 17.11% [2] - Net profit attributable to shareholders reached 112 million yuan, reflecting a 47.03% increase compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 111 million yuan, up 54.21% year-on-year [2] Business Strategy - Chengyi Pharmaceutical is committed to the dual-driven strategy of pharmaceuticals and health products, aligning with national initiatives to develop the marine economy and marine biomedicine [2] - In the pharmaceutical sector, the company focuses on a full industry chain approach, increasing R&D investment to enhance competitive advantages in clinical treatment areas such as bone and joint, cardiovascular, anti-infection, and nervous system [2] Product Development - The company prioritized key profitable products for consistency evaluation and new product development, successfully passing consistency evaluation for two specifications of sodium cytidine injection [2] - New products such as mercaptopurine tablets have been approved, and the raw material for dobutamine hydrochloride has been filed successfully [2] - As of the date of the interim report, the company has obtained a drug registration certificate for palivizumab injection [2] Market Focus - In the health product sector, the company strategically focuses on marine biomedicine and the silver economy, seizing opportunities from consumption upgrades and increased health awareness [2]

Group 1 - The company achieved a revenue of 417 million yuan in the first half of 2025, representing a year-on-year growth of 17.11% [1] - The net profit attributable to shareholders reached 112 million yuan, with a year-on-year increase of 47.03% [1] - The company is focusing on deepening its existing product lines and expanding its marketing network, enhancing collaboration with distributors and agents [1] Group 2 - The main product, Glucosamine Hydrochloride Capsules, has secured bids in most provinces through specialized academic promotion and commercial partnerships [1] - The company is strengthening management of distributors and tracking the flow of products to medical institutions and OTC, enhancing market risk control for sustainable sales growth [1] - The company is building a marketing center in Shanghai Hongqiao Business District and actively recruiting marketing talent to create a high-quality team [1] Group 3 - The company emphasizes "quality first" in production management, implementing comprehensive quality management from raw material procurement to transportation [2] - The company has strengthened audits and on-site management of raw material suppliers, advancing quality risk management [2] - The company received the "Wenzhou Green Factory" certification in 2024 for its safe, environmentally friendly, and efficient production [2] Group 4 - The company is focusing on key advantageous products in its R&D efforts, progressing with consistency evaluations and new product development [2] - The Sodium Cytidine Injection successfully passed consistency evaluation during the reporting period [2] - The company has received registration approval for the Palivizumab Injection prior to the report disclosure [3]